drugset
drugset / Trial / NCT05701826

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

NCT05701826 ↗

Phase 1 Completed 35 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797 in Chinese adults. To evaluate the effect of IV infusion duration on the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797. To explore the ED95 dosage of HRS3797 in Chinese adults.

Timeline

Start
2023-02-15
Primary completion
2023-06-02
Completion
2023-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS3797 Unknown — Intravenous

Indications

No indication recorded.